Your browser doesn't support javascript.
loading
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.
Han, Yue; Cao, Guang; Sun, Bin; Wang, Jian; Yan, Dong; Xu, Haifeng; Shi, Qinsheng; Liu, Zechuan; Zhi, Weihua; Xu, Liang; Liu, Bojun; Zou, Yinghua.
Affiliation
  • Han Y; Department of Interventional Therapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. doctorhan@163.com.
  • Cao G; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Sun B; Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
  • Wang J; Department of Interventional Radiology and Vascular Surgery, First Hospital, Peking University, Beijing, 100034, China.
  • Yan D; Department of Interventional Therapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Xu H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Shi Q; Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
  • Liu Z; Department of Interventional Radiology and Vascular Surgery, First Hospital, Peking University, Beijing, 100034, China.
  • Zhi W; Department of Interventional Therapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Xu L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Liu B; Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
  • Zou Y; Department of Interventional Radiology and Vascular Surgery, First Hospital, Peking University, Beijing, 100034, China.
BMC Gastroenterol ; 21(1): 393, 2021 Oct 20.
Article in En | MEDLINE | ID: mdl-34670512
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2021 Document type: Article Affiliation country: Country of publication: